Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 282

The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.

Rho-kinase: important new therapeutic target in cardiovascular diseases

Satoh, Kimio, Fukumoto, Yoshihiro, Shimokawa, Hiroaki·2011·American Journal of Physiology-Heart and Circulatory Physiology

Abstract

Rho-kinase (ROCKs) belongs to the family of serine/threonine kinases and is an important downstream effector of the small GTP-binding protein RhoA. There are two isoforms of Rho-kinase, ROCK1 and ROCK2, and they have different functions with ROCK1 for circulating inflammatory cells and ROCK2 for vascular smooth muscle cells. It has been demonstrated that the RhoA/Rho-kinase pathway plays an important role in various fundamental cellular functions, including contraction, motility, proliferation, and apoptosis, leading to the development of cardiovascular disease. The important role of Rho-kinase in vivo has been demonstrated in the pathogenesis of vasospasm, arteriosclerosis, ischemia-reperfusion injury, hypertension, pulmonary hypertension, stroke, and heart failure. Furthermore, the beneficial effects of fasudil, a selective Rho-kinase inhibitor, have been demonstrated for the treatment of several cardiovascular diseases in humans. Thus the Rho-kinase pathway is an important new therapeutic target in cardiovascular medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1152/ajpheart.00327.2011

Cites

138 of 138 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 138 references

Cited by

See all 282

Metadata

Authors
Satoh, K., Fukumoto, Y., & Shimokawa, H.
Venue
American Journal of Physiology-Heart and Circulatory Physiology
Published
2011-08
Volume
301
Issue
2
Pages
H287-H296
ISSN
  • 0363-6135 (ISSN-L)
  • 1522-1539
OpenAlex
W2165054234
Cited by
282
References
138
FWCI
12.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rho-kinase: important new therapeutic target in cardiovascular diseases. https://app.cochat.ai/papers/10.1152/ajpheart.00327.2011
The paper
Satoh, K., Fukumoto, Y., & Shimokawa, H. (2011). Rho-kinase: important new therapeutic target in cardiovascular diseases. American Journal of Physiology-Heart and Circulatory Physiology. https://doi.org/10.1152/ajpheart.00327.2011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.